Additionally, APOL1 increased the risk of Stage III CKD (OR: 1.23, 1.04–1.46; p‐value < 0.05) and Stage V CKD (OR: 1.60, 1.08–2.38; p‐value < 0.05), and these CKD stages mediated the increased risk of RBBB, LBBB, and IIIAVB (Figure 8). Here, APOL1 is linked to chronic kidney disease.